Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 434 record(s)

Req # A-2023-000300

Adverse Drug Reactions (ADRs). Report numbers: 001034418, 001034331.

Organization: Health Canada

9 page(s)
September 2023

Req # A-2023-000315

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-112079-480.

Organization: Health Canada

6 page(s)
September 2023

Req # A-2023-000352

Adverse Drug Reaction (ADR) for LANREOTIDE. Report number: E2B_05322380.

Organization: Health Canada

23 page(s)
September 2023

Req # A-2023-000354

Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_02989446, E2B_02341451, E2B_02841369, E2B_02804158, E2B_03015273, E2B_02405890, E2B_03009425, E2B_01335934, E2B_02096585, E2B_01892634.

Organization: Health Canada

233 page(s)
September 2023

Req # A-2023-000370

Adverse Drug Reactions (ADRs). Report numbers: E2B_05765891, E2B_06212022.

Organization: Health Canada

25 page(s)
September 2023

Req # A-2023-000376

Adverse Drug Reactions (ADRs) for ARIPIPRAZOLE. Report numbers: 001035620, 001036716, 001038374, E2B_06237436, E2B_06256332, E2B_06294631, E2B_06313611, E2B_06316334, E2B_06319965, E2B_06329894.

Organization: Health Canada

126 page(s)
September 2023

Req # A-2023-000381

Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_03009425, E2B_01335934, E2B_02096585, E2B_01892634, E2B_02393844, E2B_02387551, E2B_02826826, E2B_02867073, E2B_02455143, E2B_03044908.

Organization: Health Canada

258 page(s)
September 2023

Req # A-2023-000416

Adverse Drug Reaction (ADR). Report number: 000630138.

Organization: Health Canada

3 page(s)
September 2023

Req # A-2023-000417

Adverse Drug Reactions (ADRs). Report numbers: 000939353, E2B_03480589, E2B_03534311, 000941450, E2B_03506859, 000942086, 000945394, E2B_03892593, 000961233, 000961963.

Organization: Health Canada

142 page(s)
September 2023

Req # A-2023-000420

Adverse Drug Reactions (ADRs). Report numbers: E2B_06254676, E2B_06257384, E2B_06254451, 001032003, E2B_06256332, E2B_06249806.

Organization: Health Canada

111 page(s)
September 2023
Date modified: